Specific targets of KMT2/MLL epigenetic regulation have been shown to include hTERT (KMT2A, in melanoma) [12], several HOX genes (KMT2A) [9], ERalpha target genes in breast cancer (KMT2D) [13, 14], and androgen receptor target genes in prostate cancer (MLL1 and WDR5) [15]. This evidence concerns the gene WDR5 and breast cancer.